In this new study, Korean scientists uncovered a key genetic factor that drives fatty liver disease and found that vitamin B3 (niacin) may help counter it. The condition, now known as metabolic-associated fatty liver disease, affects about 30 percent of people worldwide and has long lacked effective targeted treatments. The breakthrough came when the research team discovered how a molecule known as miR-93 disrupts liver metabolism and fuels fat buildup, inflammation, and scarring in the liver.
The scientists showed that high levels of miR-93 block the action of SIRT1, a gene critical for healthy fat processing in liver cells. In experiments, mice with excessive miR-93 developed severe liver damage, while blocking this molecule improved insulin sensitivity, reduced fat accumulation, and restored liver function. This finding highlights miR-93 as a central trigger in the progression of fatty liver disease and a promising new target for therapy.
Most strikingly, after screening 150 already-approved drugs, researchers found that vitamin B3 was the most effective at suppressing miR-93. In treated mice, niacin lowered miR-93 levels, reactivated SIRT1, and normalized fat metabolism in the liver. The scientists therefore suggest that vitamin B3 could be a safe and affordable treatment for metabolic-associated fatty liver disease.
To read how vitamin B3 supplements have been shown to lower the risk of non-melanoma skin cancers, see this article on our website.
Anthony Fauci’s Explosive Secret Emails Exposing COVID-19 ‘Lies’ Are Uncovered
September 19, 2025The Dark Side of Sunscreen: How the ‘Personal Care’ Industry Puts Profits Before Public Health
September 19, 2025Could a Simple Vitamin Reverse the World’s Most Common Liver Disease?
News
MiR-93 – a type of RNA found in liver cells – promotes fatty liver disease, but vitamin B3 can counteract its effects. This discovery suggests a new treatment approach.
[Source: scitechdaily.com]
[Image source: Adobe Stock]
Comment
In this new study, Korean scientists uncovered a key genetic factor that drives fatty liver disease and found that vitamin B3 (niacin) may help counter it. The condition, now known as metabolic-associated fatty liver disease, affects about 30 percent of people worldwide and has long lacked effective targeted treatments. The breakthrough came when the research team discovered how a molecule known as miR-93 disrupts liver metabolism and fuels fat buildup, inflammation, and scarring in the liver.
The scientists showed that high levels of miR-93 block the action of SIRT1, a gene critical for healthy fat processing in liver cells. In experiments, mice with excessive miR-93 developed severe liver damage, while blocking this molecule improved insulin sensitivity, reduced fat accumulation, and restored liver function. This finding highlights miR-93 as a central trigger in the progression of fatty liver disease and a promising new target for therapy.
Most strikingly, after screening 150 already-approved drugs, researchers found that vitamin B3 was the most effective at suppressing miR-93. In treated mice, niacin lowered miR-93 levels, reactivated SIRT1, and normalized fat metabolism in the liver. The scientists therefore suggest that vitamin B3 could be a safe and affordable treatment for metabolic-associated fatty liver disease.
To read how vitamin B3 supplements have been shown to lower the risk of non-melanoma skin cancers, see this article on our website.
Dr. Rath Health Foundation
Related posts
Study Links Anti-Anxiety Medication to Increased Risk of Death for Dementia Patients
Read more